Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis

被引:0
作者
Caitlyn T. Solem
Montserrat Vera-Llonch
Sizhu Liu
Marc Botteman
Brenda Castiglione
机构
[1] Pharmerit International,
[2] Vertex Pharmaceuticals,undefined
来源
Health and Quality of Life Outcomes | / 14卷
关键词
Cystic fibrosis; EQ-5D; Lung function; Pulmonary exacerbation;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 112 条
[1]  
Bradley JM(2013)Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study Eur Respir J 41 571-577
[2]  
Blume SW(2003)Health values of adolescents with cystic fibrosis J Pediatr 142 133-140
[3]  
Balp MM(2002)Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis Chest 121 64-72
[4]  
Honeybourne D(2012)Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study Thorax 67 860-866
[5]  
Elborn JS(1994)Measuring the quality of life before and after bilateral lung transplantation in patients with cystic fibrosis Chest 105 911-917
[6]  
Yi MS(1998)Prenatal screening for cystic fibrosis carriers: an economic evaluation Am J Hum Genet 63 1160-1174
[7]  
Britto MT(2007)Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes Genet Med 9 695-704
[8]  
Wilmott RW(1995)The cost-effectiveness of lung transplantation. A pilot study. University of Washington Medical Center Lung Transplant Study Group Chest 108 1594-1601
[9]  
Kotagal UR(2012)Patient-reported outcome 2 years after lung transplantation: does the underlying diagnosis matter? Patient Relat Outcome Meas 3 79-84
[10]  
Eckman MH(2012)Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial Value Health 15 277-283